Bibliography
- Papers of special note have been highlighted as either of interest (*) or of considerable interest (**) to readers.
- Andrade LH, Wang YP, Andreoni S, et al. Mental disorders in megacities: findings from the Sao Paulo megacity mental health survey, Brazil. PloS One. 2012;7(2):e31879.
- Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403–439.
- Andrade LH, Baptista MC, Alonso J, et al. Days out-of-role due to common physical and mental health problems: results from the Sao Paulo Megacity Mental Health Survey, Brazil. Clinics. 2013;68(11):1392–1399.
- Lepine JP. Epidemiology, burden, and disability in depression and anxiety. J Clin Psychiatry. 2001;62(Suppl 13):4–10.
- Roy-Byrne PP, Stang P, Wittchen HU, et al. Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking. Br J Psychiatry. 2000;176:229–235.
- Kessler RC, Chiu WT, Jin R, et al. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006;63(4):415–424.
- Bystritsky A, Kerwin L, Niv N, et al. Clinical and subthreshold panic disorder. Depress Anxiety. 2010;27(4):381–389.
- Gorman JM, Kent JM, Sullivan GM, et al. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry. 2000;157(4):493–505.
- Nardi AE, Freire RC, Zin WA. Panic disorder and control of breathing. Respir Physiol Neurobiol. 2009;167(1):133–143.
- Freire RC, Machado S, Arias-Carrion O, et al. Current pharmacological interventions in panic disorder. CNS Neurol Disord Drug Targets. 2014;13(6):1057–1065.
- Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry. 2008;9(4):248–312.
- Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):S1.
- Freire RC, Hallak JE, Crippa JA, et al. New treatment options for panic disorder: clinical trials from 2000 to 2010. Expert Opin Pharmacother. 2011;12(9):1419–1428.
- Bandelow B, Behnke K, Lenoir S, et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J Clin Psychiatry. 2004;65(3):405–413.
- Kjernisted K, McIntosh D. Venlafaxine extended release (XR) in the treatment of panic disorder. Ther Clin Risk Manag. 2007;3(1):59–69.
- Batelaan NM, De Graaf R, Penninx BW, et al. The 2-year prognosis of panic episodes in the general population. Psychol Med. 2010;40(1):147–157.
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-III. 3d ed. Washington (DC): American Psychiatric Association; 1980.
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-III-R. 3rd ed. Washington (DC): American Psychiatric Association; 1987.
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. 4 ed. Washington (DC): American Psychiatric Press; 1994.
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington (DC): American Psychiatric Association; 2013.
- Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
- Simon NM, Otto MW, Worthington JJ, et al. Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. J Clin Psychiatry. 2009;70(11):1563–1570.
** One of the two randomized controlled double-blind clinical trials for treatment–resistant panic disorder (phase II). Also includes the only head-to-head randomized clinical trial for treatment resistant panic disorder (phase III).
- Hirschmann S, Dannon PN, Iancu I, et al. Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2000;20(5):556–559.
* One of the two randomized controlled double-blind clinical trials for treatment–resistant panic disorder.
- Baetz M, Bowen RC. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry. 1998;43(1):73–77.
- Hoge EA, Worthington III JJ, Kaufman RE, et al. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr. 2008;13(6):522–527.
- Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open-label study. Hum Psychopharmacol. 2002;17(7):329–333.
- Hollifield M, Thompson PM, Ruiz JE, et al. Potential effectiveness and safety of olanzapine in refractory panic disorder. Depress Anxiety. 2005;21:33–40.
- Sepede G, De Berardis D, Gambi F, et al. Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol. 2006;26(1):45–49.
- Pollack MH, Otto MW, Kaspi SP, et al. Cognitive behavior therapy for treatment-refractory panic disorder. J Clin Psychiatry. 1994;55(5):200–205.
- Heldt E, Blaya C, Isolan L, et al. Quality of life and treatment outcome in panic disorder: cognitive behavior group therapy effects in patients refractory to medication treatment. Psychother Psychosom. 2006;75(3):183–186.
- Heldt E, Manfro GG, Kipper L, et al. One-year follow-up of pharmacotherapy-resistant patients with panic disorder treated with cognitive-behavior therapy: outcome and predictors of remission. Behav Res Ther. 2006;44(5):657–665.
- Heldt E, Manfro GG, Kipper L, et al. Treating medication-resistant panic disorder: predictors and outcome of cognitive-behavior therapy in a Brazilian public hospital. Psychother Psychosom. 2003;72(1):43–48.
- Bandelow B, Rüther E. Treatment-resistant panic disorder. CNS Spectr. 2004;9(10):725–739.
- Gao K, Wu R, Kemp DE, et al. Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo-controlled trial. J Clin Psychiatry. 2014;75(10):1062–1068.
- Chen YC, Chen CK, Wang LJ. Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a pilot study. BMC Psychiatry. 2012;12:162.
- Hershenberg R, Gros DF, Brawman-Mintzer O. Role of atypical antipsychotics in the treatment of generalized anxiety disorder. CNS Drugs. 2014;28(6):519–533.
- George MS, Padberg F, Schlaepfer TE, et al. Controversy: repetitive transcranial magnetic stimulation or transcranial direct current stimulation shows efficacy in treating psychiatric diseases (depression, mania, schizophrenia, obsessive-complusive disorder, panic, posttraumatic stress disorder). Brain Stimul. 2009;2(1):14–21.
- Cristancho MA, Cristancho P, O’Reardon JP. Other therapeutic psychiatric uses of superficial brain stimulation. Handb Clin Neurol. 2013;116:415–422.